US equities |
MU $992.07 ▼-3.59% META $747.87 ▲+4.06% NVDA $226.44 ▼-1.24% SNDK $1,480.92 ▼-6.38% SPCX $163.83 ▲+0.78% AMD $590.53 ▼-2.89% MSFT $538.97 ▲+0.73% TSLA $379.33 ▼-0.88%
FinancialContent

Alpha Tau Medical Ltd. - Ordinary Shares (NQ:DRTS)

14.21 -0.20 (-1.36%)
Delayed Quote Updated: 2:17 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alpha Tau Medical Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
News headline image
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
News headline image
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Expert Ratings for Alpha Tau Medical ↗
 
Via Benzinga
News headline image
Analyst Ratings for Alpha Tau Medical ↗
 
Via Benzinga
News headline image
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Treats First Patient with Recurrent Lung Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
-Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this patient population - 
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q2 2024 ↗
DRTS stock results show that Alpha Tau Medical beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q1 2024 ↗
DRTS stock results show that Alpha Tau Medical beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q4 2023 ↗
DRTS stock results show that Alpha Tau Medical beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Why Alpha Tau Medical Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket ↗
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) rose 62.4% to $3.15 in pre-market trading after falling 11% on Monday. Tivic Health Systems inked a pact to make its products available on... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
We're starting the final day of trading this week with a dive into the biggest pre-market stock movers worth watching for Friday! 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >